Inozyme Pharma Announces Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma, Inc. (NASDAQ:INZY) has announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from its ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).
September 26, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inozyme Pharma's positive interim data from its ongoing Phase 1/2 clinical trials of INZ-701 could potentially boost investor confidence and positively impact the company's stock price in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. Given that these trials are for a novel therapeutic, the positive results could have a significant impact on Inozyme Pharma's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100